New CEO for Aridhia
News Apr 27, 2015
Roche joined the company in 2014 as Chief Commercial Officer (CCO) and over the last 12 months has brought a new commercial focus to the company as Aridhia transformed to a SaaS based business model.
“During this critical time of growth, there is no better person to lead Aridhia than Chris Roche,” says David Sibbald. “Chris is a proven leader with a deep understanding of data science, business vision and the ability to bring people together. His ability to rapidly scale data businesses and corporate experience is precisely what Aridhia needs as we enter our next chapter of innovation and growth.”
Chris Roche says: “Aridhia is a rare company that has a real opportunity to change the way we use data and analytics to manage chronic disease and accelerate collaborative research. I am truly honoured to be part of that story. My focus is now to accelerate our own business model by opening international hubs and building specific disease focused solutions with our clinical partners” The company recently announced it was partnering with fellow Scottish health tech pioneer Craneware to target the US market.
Last year Aridhia launched its SaaS based data innovation platform, AnalytiXagility, to offer translational data services to research, precision medicine and integrated care teams. These teams bring their data to the platform and use the in-built tools and processing power to collaboratively build analytical models in a secure and safe environment. These models are then deployed into clinical practice from AnalytiXagility via modern day apps. Part of Aridhia’s translational services included data innovation labs where Aridhia augments their client’s teams with data science and application development capability.
Roche says: “Since the launch of AnalytiXagility we’ve worked with research, population health and precision medicine projects. We’ve enabled teams from a wide variety of disease types including; diabetes, traumatic brain injury, multiple sclerosis and ovarian cancer to name just a few. The breadth of data we are now processing includes genomic, clinical, imaging, sensor generated and waveform data from bedside monitors.”
As well as being available from the UK Government G-Cloud framework, AnalytiXagility is also the informatics platform deployed at the Stratified Medicine Scotland Innovation Centre (SMS-IC). Roche says “Using the deployment at SMS-IC, we are the only Scottish company to date in being part of a successful Horizon2020 bid the EU’s R&D funding stream. We will be analysing data from universities, healthcare providers and industrial partners in 10 EU member states to optimise research and the delivery of health and wellbeing to the European population. A great advert for Scotland.”
Chris will lead a workforce of 60 employees, encompassing data scientists, information governance specialists, computer scientists, software developers and healthcare experts.
Artificial intelligence is having a positive impact on drug development and personalized medicine. With the ability to efficiently analyze small datasets that focus on the specific disease of interest, small dataset-based AI platforms can rationally design optimal drug combinations that are effective and based on real experimental data and not mechanistic assumptions or predictive modeling.READ MORE